18.7DKK
83.68 BDKK
232.26 BDKK
3.15 B
About NOVO NORDISK B A/S
Sector
CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Website
Employees (FY)
63.37 K
Founded
1931
ISIN
DK0062498333
FIGI
BBG000F8TZ33
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where NOVO_B is featured.
Frequently Asked Questions
The current price of NOVO_B is 862.7 DKK — it has decreased by 0.99% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXCOP exchange NOVO NORDISK B A/S stocks are traded under the ticker NOVO_B.
NOVO NORDISK B A/S is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
NOVO_B stock is 2.21% volatile and has beta coefficient of 1.50. Check out the list of the most volatile stocks — is NOVO NORDISK B A/S there?
One year price forecast for NOVO NORDISK B A/S has a max estimate of 1144.3 DKK and a min estimate of 530.0 DKK.
NOVO_B earnings for the last quarter are 5.00 DKK whereas the estimation was 4.81 DKK which accounts for 4.02% surprise. Estimated earnings for the next quarter are 4.58 DKK. See more details about NOVO NORDISK B A/S earnings.
NOVO NORDISK B A/S revenue for the last quarter amounts to 58.73 B DKK despite the estimated figure of 57.78 B DKK. In the next quarter revenue is expected to reach 62.62 B DKK.
Yes, you can track NOVO NORDISK B A/S financials in yearly and quarterly reports right on TradingView.
NOVO_B stock has risen by 0.71% compared to the previous week, the month change is a 5.55% fall, over the last year NOVO NORDISK B A/S has showed a 48.82% increase.
NOVO_B net income for the last quarter is 21.96 B DKK, while the quarter before that showed 22.48 B DKK of net income which accounts for −2.29% change. Track more NOVO NORDISK B A/S financial stats to get the full picture.
Today NOVO NORDISK B A/S has the market capitalization of 3.88 T, it has increased by 0.52% over the last week.
NOVO NORDISK B A/S dividend yield was 1.35% in 2023, and payout ratio reached 50.35%. The year before the numbers were 1.32% and 50.59% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, NOVO_B shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK B A/S stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 63.37 K employees. See our rating of the largest employees — is NOVO NORDISK B A/S on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO NORDISK B A/S technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO NORDISK B A/S stock shows the buy signal. See more of NOVO NORDISK B A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NOVO NORDISK B A/S future price: according to them, NOVO_B price has a max estimate of 1144.28 DKK and a min estimate of 530.00 DKK. Read a more detailed NOVO NORDISK B A/S forecast: see what analysts think of NOVO NORDISK B A/S and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK B A/S EBITDA is 111.87 B DKK, and current EBITDA margin is 47.96%. See more stats in NOVO NORDISK B A/S financial statements.